Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
RIGL

RIGL - Rigel Pharmaceuticals Inc Stock Price, Fair Value and News

$32.86+0.78 (+2.43%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

91/100

RIGL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

91/100

RIGL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RIGL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RIGL Price Action

Last 7 days

9.8%

Last 30 days

2.3%

Last 90 days

26.6%

Trailing 12 Months

54.3%

RIGL RSI Chart

RIGL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RIGL Valuation

Market Cap

605.0M

Price/Earnings (Trailing)

1.66

Price/Sales (Trailing)

2.02

EV/EBITDA

4.8

Price/Free Cashflow

7.63

RIGL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RIGL Fundamentals

RIGL Revenue

Revenue (TTM)

299.8M

Rev. Growth (Yr)

10.28%

Rev. Growth (Qtr)

-15.74%

RIGL Earnings

Earnings (TTM)

364.2M

Earnings Growth (Yr)

-24.39%

Earnings Growth (Qtr)

-96.77%

RIGL Profitability

EBT Margin

40.69%

Return on Equity

91.08%

Return on Assets

72.18%

Free Cashflow Yield

13.1%

RIGL Investor Care

Shares Dilution (1Y)

3.39%

Diluted EPS (TTM)

19.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2026299.8M000
2025203.1M267.9M282.1M294.3M
2024120.3M130.3M157.5M179.3M
2023129.6M126.6M132.4M116.9M
202285.0M88.5M89.4M120.2M
2021133.9M144.1M147.3M149.2M
2020102.4M108.0M105.6M108.6M
201957.1M65.8M81.7M59.3M
201802.7M7.6M44.5M
201716.4M12.4M8.5M4.5M
201600020.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Rigel Pharmaceuticals Inc

RIGL
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. It also develops Fostamatinib that has conducted phase III clinical trials for the treatment of warm autoimmune hemolytic anemia; has completed FOCUS phase III clinical trial for the treatment of hospitalized high-risk patients COVID-19; and that is in phase II/III clinical trials for the treatment of COVID-19 in hospitalized patients. In addition, the company's other clinical programs include interleukin receptor-associated kinase inhibitor program and a receptor-interacting serine/threonine-protein kinase inhibitor program in clinical development with partner Eli Lilly and Company. Further, it has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
 CEO
 WEBSITErigel.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES155

Rigel Pharmaceuticals Inc Frequently Asked Questions

RIGL is the stock ticker symbol of Rigel Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Rigel Pharmaceuticals Inc is 605.02 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, RIGL's PE ratio (Price to Earnings) is 1.66 and Price to Sales (PS) ratio is 2.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RIGL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Rigel Pharmaceuticals Inc has provided 0.033 (multiply by 100 for percentage) rate of return.